Poll

Patient-Reported Outcome Measures in PsA

May 2023

Current Issue

May 2023

Volume 63

Issue 5

Research Summaries

FDA Alert

First Oral Treatment to Prevent Recurring Clostridioides difficile Infection Approved

06/01/2023

Jessica Ganga

The FDA has approved the first orally administered treatment for the gut infection—clostridioides difficile.

06/01/2023

Research Summary

Blood Test Detects Residual Disease For Adults With AML in Remission Prior to Bone Marrow Transplant

05/31/2023

Anthony Calabro, MA

Researchers performed a retrospective observational study to determine whether DNA sequencing can detect residual disease in adults with acute myeloid leukemia (AML) in first remission.

05/31/2023

Research Summary

High Long-term Survivability, Patient Satisfaction After Robotic-arm—assisted Medial UKA

05/31/2023

Anthony Calabro, MA

The authors set out to determine implant survivorship and patient satisfaction of robotic-arm—assisted unicompartmental knee arthroplasty at 10-years follow-up.

05/31/2023

research summary

research summary

Opioids Are the Most Frequent Substance in Pediatric Poisoning Fatalities

05/30/2023

Leigh Precopio

To guide prevention efforts for fatal poisonings in pediatric patients, the authors of a recent study examined characteristics of death from poisoning in young children within the United States.

05/30/2023

Conference Coverage

Conference Coverage

Making the Most of Your Conversations About Advance Care Planning

05/30/2023

Anthony Calabro, MA

In their presentation at the 48th ONS Congress, in San Antonio, Texas, Denise Nicholson BSN, RN and Colleen Nevins DNP, RN, CNE describe the best practices for advance care planning conversations and review...

05/30/2023

Poll

What do you observe as the main reason for nonadherence to urate-lowering therapy among your patients with gout?

Patients tend to feel better between flares.

Patients do not want to begin treatment with another medication.

Patients can be discouraged from continuing treatment if they experience flares at the initiation of urate-lowering therapy.

Submit Answer